Chardan Capital maintains Buy on Palvella Therapeutics; $240 target
Benzinga reports Chardan Capital maintained a Buy rating on Palvella Therapeutics and kept its $240.00/share price target.
Benzinga reports Chardan Capital maintained a Buy rating on Palvella Therapeutics and kept its $240.00/share price target.